Champions Oncology Q1 Results: Adj. EPS up 400% to $0.05

0 min read | Published on 11 Sept 2026, 03:18 AM |Updated on 11 Sept 2026, 03:18 AM

Reviewed by

Naman SScanX News Team

Add as a preferred
source on Google

Key Highlights

Adjusted EPS rose 400% YoY to $0.05 from $0.01
Sales increased 8.84% to $15.232 million
Revenue grew from $13.995 million in the prior year quarter
Profit growth significantly outpaced top-line expansion

*this image is generated using AI for illustrative purposes only.

Champions Oncology (NASDAQ: CSBR) reported first-quarter adjusted earnings per share of $0.05, marking a sharp turnaround from the prior year period.

The company logged sales of $15.232 million for the quarter, reflecting steady top-line momentum amid improving profitability metrics.

Financial Performance

Metric	Current Quarter	Prior Year Quarter	Change
Adjusted EPS	$0.05	$0.01	+400%
Sales	$15.232 million	$13.995 million	+8.84%

Earnings per share surged fourfold compared to $0.01 in the same quarter last year. This profit expansion occurred alongside an 8.84% increase in sales, which grew from $13.995 million to $15.232 million.

What the Numbers Show

Profitability expanded at a significantly faster rate than revenue generation. While sales grew by less than 9%, adjusted EPS increased by 400%. This divergence suggests improved operating leverage or margin expansion during the period, as the bottom line reacted more aggressively to top-line growth than in the prior year.

What specific operational changes or cost-saving measures drove the disproportionate 400% surge in adjusted EPS relative to the modest 8.84% sales growth?

How sustainable is this margin expansion trajectory given the current competitive landscape in the oncology sector?

Will Champions Oncology reinvest its improved profitability into R&D for new pipeline candidates or prioritize shareholder returns through buybacks or dividends?

Champions Oncology adds in-house SPECT/CT imaging to radiopharma platform

0 min read | Published on 01 Sept 2026, 07:09 PM |Updated on 01 Sept 2026, 07:09 PM

Reviewed by

Shriram SScanX News Team

Add as a preferred
source on Google

Key Highlights

Champions Oncology adds in-house SPECT/CT imaging to its radiopharmaceutical platform
New capability enables longitudinal visualization of radiopharmaceutical uptake in vivo
Integration connects imaging data with terminal biodistribution and PDX tumor biology
Platform supports improved model selection and biomarker identification for sponsors
Entire workflow remains U.S.-based within existing translational oncology services

*this image is generated using AI for illustrative purposes only.

Champions Oncology, Inc. announced the expansion of its integrated radiopharmaceutical development platform with new in-house SPECT/CT imaging capabilities on September 1, 2026. The addition strengthens the company's translational oncology research solutions by enabling longitudinal visualization of radiopharmaceutical uptake.

Integrated Imaging Capabilities

The new SPECT/CT imaging allows researchers to visualize and quantify radiopharmaceutical uptake in vivo over time. This capability extends Champions' existing services, which include radiolabeling, biodistribution studies, efficacy testing, and clinically relevant oncology models.

By integrating imaging with terminal biodistribution and therapeutic response data, sponsors can now connect dynamic uptake patterns with the molecular characteristics of tumor models. This approach supports the evaluation of not just where a radiopharmaceutical localizes, but how that localization relates to target expression and therapeutic response.

Enhanced PDX Model Utility

Champions applies this integrated approach to its portfolio of clinically annotated patient-derived xenograft (PDX) models. The combination of longitudinal imaging and terminal analysis enables richer translational datasets. These datasets support predictive approaches to radiopharmaceutical development, including improved model selection and biomarker identification.

The workflow remains entirely U.S.-based, connecting longitudinal imaging with biodistribution and efficacy insights in a single operational environment.

How might Champions Oncology's new in-house SPECT/CT capabilities impact the timeline and cost efficiency for biotech partners developing novel radiopharmaceuticals?

Will this expansion allow Champions to capture a larger share of the growing theranostics market, and if so, what is the projected revenue contribution from imaging services over the next three years?

How does the integration of longitudinal imaging with PDX models differentiate Champions' data offerings from competitors who rely solely on terminal biodistribution studies?